The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara ... and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection ...

a single-dose vial for subcutaneous injection at 45 mg/0.5 mL and a single-dose vial for intravenous infusion at 130 mg/26 mL ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba ... is available in both subcutaneous injection and intravenous infusion ...

After 44 weeks, 43.5% of paediatric patients receiving Stelara 90mg every every weeks and 60% of those receiving Stelara 90mg every 12 weeks achieved clinical remission, with 22.7% and 28% achieving ...

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal ...